Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00093873
Recruitment Status : Completed
First Posted : October 8, 2004
Last Update Posted : May 15, 2013
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Tumors Drug: Anti-angiogenesis Drug: AMG 706 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors
Study Start Date : July 2003
Actual Primary Completion Date : February 2006
Actual Study Completion Date : December 2006

Arm Intervention/treatment
Experimental: AMG 706
AMG 706 QD
Drug: Anti-angiogenesis
Anti-angiogenesis

Drug: AMG 706
Anti-angiogenesis




Primary Outcome Measures :
  1. Dose limiting toxicity [ Time Frame: Cycle 1 ]

Secondary Outcome Measures :
  1. Dose selection [ Time Frame: Study completion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Inclusion Criteria: Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00093873


Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT00093873    
Other Study ID Numbers: 20030116
First Posted: October 8, 2004    Key Record Dates
Last Update Posted: May 15, 2013
Last Verified: May 2013
Keywords provided by Amgen:
Cancer
antiangiogenesis
Solid Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Motesanib diphosphate
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action